Dyne Therapeutics [DYN] vs Vertex [VRTX] Detailed Stock Comparison
Dyne Therapeutics
NASDAQ
Loading...
Vertex
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Dyne Therapeutics wins in 4 metrics, Vertex wins in 11 metrics, with 0 ties. Vertex appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Dyne Therapeutics | Vertex | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -3.88 | 28.68 | Dyne Therapeutics |
| Price-to-Book Ratio | 2.61 | 6.02 | Dyne Therapeutics |
| Debt-to-Equity Ratio | 21.19 | 8.89 | Vertex |
| PEG Ratio | -0.10 | -0.22 | Vertex |
| EV/EBITDA | -2.95 | 20.53 | Dyne Therapeutics |
| Profit Margin (TTM) | 0.00% | 31.86% | Vertex |
| Operating Margin (TTM) | 0.00% | 38.93% | Vertex |
| EBITDA Margin (TTM) | N/A | 38.93% | N/A |
| Return on Equity | -61.32% | 22.77% | Vertex |
| Return on Assets (TTM) | -35.45% | 13.09% | Vertex |
| Free Cash Flow (TTM) | $-294.75M | $-978.00M | Dyne Therapeutics |
| 1-Year Return | -62.43% | -16.36% | Vertex |
| Price-to-Sales Ratio (TTM) | N/A | 9.06 | N/A |
| Enterprise Value | $1.30B | $98.55B | Vertex |
| EV/Revenue Ratio | N/A | 8.63 | N/A |
| Gross Profit Margin (TTM) | N/A | 86.25% | N/A |
| Revenue per Share (TTM) | $0 | $44 | Vertex |
| Earnings per Share (Diluted) | $-3.88 | $14.06 | Vertex |
| Beta (Stock Volatility) | 1.08 | 0.43 | Vertex |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Dyne Therapeutics vs Vertex Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Dyne Therapeutics | -3.14% | 2.26% | -4.89% | 54.65% | 68.89% | -50.31% |
| Vertex | -0.10% | 1.92% | 1.94% | -12.30% | -15.10% | -0.70% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Dyne Therapeutics | -62.43% | -4.09% | -27.38% | -44.52% | -44.52% | -44.52% |
| Vertex | -16.36% | 37.41% | 84.75% | 252.43% | 1,018.23% | 1,674.89% |
News Based Sentiment: Dyne Therapeutics vs Vertex
Dyne Therapeutics
News based Sentiment: POSITIVE
October was a strong month for Dyne Therapeutics, highlighted by key regulatory approvals (FDA Breakthrough Therapy and Japanese Orphan Drug designation) for DYNE-251, coupled with positive analyst upgrades and insider buying activity. While the company remains pre-revenue, these developments signal significant progress and potential for future growth, making it a noteworthy investment story.
Vertex
News based Sentiment: MIXED
October presented a mixed bag for Vertex, with a major FDA approval and positive financial results offset by a failed clinical trial and increased operating expenses. The strategic pipeline advancements and strong financial position suggest continued growth potential, but investors should monitor the impact of the trial setback and expense increases.
Performance & Financial Health Analysis: Dyne Therapeutics vs Vertex
| Metric | DYN | VRTX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.95B | $103.40B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 2,426,520 | 1,835,420 |
| 90 Day Avg. Volume | 2,473,740 | 1,652,450 |
| Last Close | $12.65 | $402.90 |
| 52 Week Range | $6.36 - $35.90 | $362.50 - $519.88 |
| % from 52W High | -64.76% | -22.50% |
| All-Time High | $47.45 (Aug 19, 2024) | $519.88 (Nov 04, 2024) |
| % from All-Time High | -73.34% | -22.50% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.12% |
| Quarterly Earnings Growth | N/A | 0.12% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.32% |
| Operating Margin (TTM) | 0.00% | 0.39% |
| Return on Equity (TTM) | -0.61% | 0.23% |
| Debt to Equity (MRQ) | 21.19 | 8.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $5.00 | $67.02 |
| Cash per Share (MRQ) | $4.81 | $24.90 |
| Operating Cash Flow (TTM) | $-359,560,000 | $3.85B |
| Levered Free Cash Flow (TTM) | $-222,398,000 | $2.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Dyne Therapeutics vs Vertex
| Metric | DYN | VRTX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -3.88 | 28.68 |
| Forward P/E | -4.13 | 21.49 |
| PEG Ratio | -0.10 | -0.22 |
| Price to Sales (TTM) | N/A | 9.06 |
| Price to Book (MRQ) | 2.61 | 6.02 |
| Market Capitalization | ||
| Market Capitalization | $1.95B | $103.40B |
| Enterprise Value | $1.30B | $98.55B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 8.63 |
| Enterprise to EBITDA | -2.95 | 20.53 |
| Risk & Other Metrics | ||
| Beta | 1.08 | 0.43 |
| Book Value per Share (MRQ) | $5.00 | $67.02 |
Financial Statements Comparison: Dyne Therapeutics vs Vertex
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | DYN | VRTX |
|---|---|---|
| Revenue/Sales | $0 | $2.96B |
| Cost of Goods Sold | N/A | $407.50M |
| Gross Profit | N/A | $2.56B |
| Research & Development | $99.24M | $978.40M |
| Operating Income (EBIT) | $-115.79M | $1.15B |
| EBITDA | $-110.26M | $1.34B |
| Pre-Tax Income | $-110.86M | $1.28B |
| Income Tax | N/A | $250.10M |
| Net Income (Profit) | $-110.86M | $1.03B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | DYN | VRTX |
|---|---|---|
| Cash & Equivalents | $472.26M | $4.67B |
| Total Current Assets | $689.50M | $10.01B |
| Total Current Liabilities | $33.88M | $3.78B |
| Long-Term Debt | $18.22M | $1.65B |
| Total Shareholders Equity | $668.97M | $16.50B |
| Retained Earnings | $-1.07B | $10.25B |
| Property, Plant & Equipment | $34.19M | $2.63B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | DYN | VRTX |
|---|---|---|
| Operating Cash Flow | $-110.37M | $404.90M |
| Capital Expenditures | $-981,000 | $-40.70M |
| Free Cash Flow | $-106.87M | $778.20M |
| Debt Repayment | N/A | $-1.30M |
| Common Stock Repurchase | N/A | $-696.60M |
Short Interest & Institutional Ownership Analysis
| Metric | DYN | VRTX |
|---|---|---|
| Shares Short | 15.30M | 4.05M |
| Short Ratio | 6.78 | 2.83 |
| Short % of Float | 0.12% | 0.02% |
| Average Daily Volume (10 Day) | 2,426,520 | 1,835,420 |
| Average Daily Volume (90 Day) | 2,473,740 | 1,652,450 |
| Shares Outstanding | 102.32M | 256.94M |
| Float Shares | 122.63M | 255.58M |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.95% | 0.98% |
Dividend Analysis & Yield Comparison: Dyne Therapeutics vs Vertex
| Metric | DYN | VRTX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |